NGM Biopharmaceuticals Investor Relations Material
Latest events
Study Result
NGM Biopharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from NGM Biopharmaceuticals Inc
Access all reports
NGM Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of liver and metabolic diseases, retinal diseases, and cancer. The company's key products in development include NGM707, a dual antagonist monoclonal antibody for advanced metastatic solid tumors, and Aldafermin, an engineered analog of a human hormone aimed at treating liver diseases such as non-alcoholic steatohepatitis. Additionally, NGM Biopharmaceuticals works on a variety of other drug candidates targeted at different therapeutic areas, using a biologics-based platform to create and evaluate monoclonal antibodies and other proteins. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
NGM
Country
🇺🇸 United States